Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 4/20 | 0.58 |
| ▸ | TDO2 | P48775 | 8/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.49 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2526465 | 0.86 | NPC1 (0.71) | MAP3K11NPC1CYP3A4CYP2D6IMPDH2 | |
| SCHEMBL7088454 | 0.83 | PIK3CD (0.62) | MAP3K11NPC1ASH1LCASP3SENP7 | |
| SCHEMBL29713619 | 0.81 | TDO2 (0.70) | TDO2NR4A2PDGFRBPDGFRAALOX5 | |
| SCHEMBL7089602 | 0.79 | NPC1 (0.59) | MAP3K11NPC1CYP3A4CYP2D6CASP3 | |
| SCHEMBL28377762 | 0.78 | NR4A2 (0.81) | TDO2NR4A2PDGFRBPDGFRAALOX5 | |
| SCHEMBL16918805 | 0.78 | NPC1 (0.62) | MAP3K11NPC1NR4A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL27534537 | 0.77 | NPC1 (0.57) | MAP3K11NPC1CYP3A4CYP2D6CASP3 | |
| SCHEMBL3872843 | 0.77 | TDO2 (0.53) | TDO2NR4A2PDGFRBPDGFRAALOX5 | |
| SCHEMBL17097194 | 0.77 | TDO2 (0.60) | TDO2PDGFRBPDGFRADYRK1ADYRK2 | |
| SCHEMBL28416622 | 0.77 | NR4A2 (0.78) | TDO2NR4A2PDGFRBPDGFRAALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109963561-A | Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 | 默沙东公司 | 2019-07-02 | — | — | CN | claimed |
| US-9822092-B2 | ArylSulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-8975439-B2 | Arylsulfonamide based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2015-03-10 | — | — | US | disclosed |
| US-20150045398-A1 | ArylSulfonamide-Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2015-02-12 | — | — | US | disclosed |
| US-20130096105-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-8362063-B2 | Arylsulfonamide based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-20120258954-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| US-8222424-B2 | Arylsulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| CN-1247589-C | Tricyclic derivatives of indole with antiangiogenic activity | SIGMA TAU IND FARMACEUTI (IT) | 2006-03-29 | — | — | CN | disclosed |
| CN-1471535-A | Tricyclic derivatives of indole with antiangiogenic activity | ϣ��������ҩ��ҵ��˾ | 2004-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | MMP11, MMP10, MMP9 | MAP3K11 729/4885TDO2 360/4885NPC1 1157/4885 |
| US-20150045398-A1 | ArylSulfonamide-Based Matrix Metalloprotease Inhibitors | MMP11, MMP10, MMP9 | MAP3K11 729/4885TDO2 360/4885NPC1 1157/4885 |
| US-20120258954-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | MMP11, MMP9, MMP10 | MAP3K11 657/4885TDO2 351/4885NPC1 1236/4885 |
| US-20130096105-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | MMP11, MMP9, MMP10 | MAP3K11 657/4885TDO2 351/4885NPC1 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.